Relevant bibliographies by topics / Nanoparticulate Drug Carriers

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Nanoparticulate Drug Carriers'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nanoparticulate Drug Carriers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nanoparticulate Drug Carriers"

1

Crossen, Samantha Lokelani, and Tarun Goswami. "Nanoparticulate carriers for drug delivery." Journal of Pharmaceutical and Biopharmaceutical Research 4, no. 1 (2022): 237–47. http://dx.doi.org/10.25082/jpbr.2022.01.001.

Full text
Abstract:
Drug delivery with nanoparticulate carriers is a new and upcoming research area that is making major changes within the pharmaceutical industry. Nanoparticulate carriers are discussed, particularly, engineered nanoparticulate carriers used as drug delivery systems for targeted delivery. Nanoparticulate carriers that are used for drug delivery systems include polymers, micelles, dendrimers, liposomes, ceramics, metals, and various forms of biological materials. The properties of these nanoparticulate carriers are very advantageous for targeted drug delivery and result in efficient drug accumulation at the targeted area of interest, reduced drug toxicity, reduced systemic side effects, and more efficient use of the drug overall. Nanoparticlulate carriers are effective in passing various biological impediments and have a relatively high cellular uptake compared to that of microparticulate carriers, which allows for the drug agent to reach a targeted cell or tissue. The use of nanoparticulate carriers for drug delivery results in a prolonged and sustained release of the drug which ultimately reduces the cost and amount of doses that need to be administered to the patient. Currently, there is extensive research of nanoparticles as drug delivery carriers for challenging disease treatment cases such as cancer, HIV, and diabetes.
APA, Harvard, Vancouver, ISO, and other styles
2

Holback, Hillary, and Yoon Yeo. "Intratumoral Drug Delivery with Nanoparticulate Carriers." Pharmaceutical Research 28, no. 8 (January 7, 2011): 1819–30. http://dx.doi.org/10.1007/s11095-010-0360-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Karen C., and Yoon Yeo. "Extracellular stability of nanoparticulate drug carriers." Archives of Pharmacal Research 37, no. 1 (November 12, 2013): 16–23. http://dx.doi.org/10.1007/s12272-013-0286-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

EZEGBE, CHEKWUBE, Ogechukwu Umeh, and Sabinus Ofoefule. "Drug Carriers." Journal of Current Biomedical Research 2, no. 1 (February 28, 2022): 77–105. http://dx.doi.org/10.54117/jcbr.v2i1.3.

Full text
Abstract:
In recent years, there has been an exponential interest in the development of novel drug delivery systems using drug carriers. Drug carriers offer significant advantages over the conventional drug delivery systems in terms of high stability, high specificity, high drug loading capacity, controlled release of drug and ability to deliver both hydrophilic and hydrophobic drugs. As a result of their unique behaviors, drug carriers have a wide range of biomedical and industrial applications. Nanospheres are associated with a lot of benefits such as ease of administration to target sites, reduction in toxicity level and ease of passage via the capillary vessels. Hydrogel nanoparticles are useful in the treatment of inflammatory diseases, as bioresponsive hydrogels in drug delivery system and as a carrier in controlled drug delivery system. Carbon nanotubes have a large surface area which has the ability to adsorb or conjugate with a wide variety of therapeutic and diagnostic agents. They are useful in the areas of gene delivery, tissue regeneration and biosensor diagnosis. Liposomes are known to target a drug to a specific site. They entrap drugs which are released for subsequent absorption. They are used to achieve active targeting, increase efficacy and therapeutic index of drugs. Niosomes improve the solubility and oral bioavailability of poorly soluble drugs. They protect drugs from biological environment, increase the stability of entrapped drugs and they can easily reach the site of action. Aquasomes are nanoparticulate carriers that can be characterized for structural analysis. They preserve conformational integrity and biochemical stability of drugs. Ethosomes are noninvasive delivery carriers that enable drugs to reach the deep skin layers and the systemic circulation. They contain phospholipids which could be in form of phosphatidyl choline (PC), hydrogenated PC, phosphatidic acid (PA), Phosphatidyl serine (PS) and phosphatidyl inositol (PI). Ethosomes are known to increase skin permeation of drugs, improve biological activity and pharmacodynamics profile of drugs. This review aims to emphasize the importance of drug carriers in drug delivery system, and applications of drug carriers in various areas of research, technology and treatment.
APA, Harvard, Vancouver, ISO, and other styles
5

Žigrayová, Dominika, Veronika Mikušová, and Peter Mikuš. "Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers." Viruses 15, no. 3 (February 28, 2023): 647. http://dx.doi.org/10.3390/v15030647.

Full text
Abstract:
Current antiviral therapy research is focused on developing dosage forms that enable highly effective drug delivery, providing a selective effect in the organism, lower risk of adverse effects, a lower dose of active pharmaceutical ingredients, and minimal toxicity. In this article, antiviral drugs and the mechanisms of their action are summarized at the beginning as a prerequisite background to develop relevant drug delivery/carrier systems for them, classified and briefly discussed subsequently. Many of the recent studies aim at different types of synthetic, semisynthetic, and natural polymers serving as a favorable matrix for the antiviral drug carrier. Besides a wider view of different antiviral delivery systems, this review focuses on advances in antiviral drug delivery systems based on chitosan (CS) and derivatized CS carriers. CS and its derivatives are evaluated concerning methods of their preparation, their basic characteristics and properties, approaches to the incorporation of an antiviral drug in the CS polymer as well as CS nanoparticulate systems, and their recent biomedical applications in the context of actual antiviral therapy. The degree of development (i.e., research study, in vitro/ex vivo/in vivo preclinical testing), as well as benefits and limitations of CS polymer and CS nanoparticulate drug delivery systems, are reported for particular viral diseases and corresponding antivirotics.
APA, Harvard, Vancouver, ISO, and other styles
6

Bhosale, Rohit R., Riyaz Ali M. Osmani, Rudra Vaghela, Tamal Deb, H. V. Gangadharappa, and Afrasim Moin. "Dendrimers: Inimitable Nanoparticulate Drug Carriers—A Comprehensive Review." Advanced Science, Engineering and Medicine 8, no. 4 (April 1, 2016): 251–70. http://dx.doi.org/10.1166/asem.2016.1862.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Md., Shadab, Shadabul Haque, Ravi Sheshala, Lim Wei Meng, Venkata Srikanth Meka, and Javed Ali. "Recent Advances in Non-Invasive Delivery of Macromolecules using Nanoparticulate Carriers System." Current Pharmaceutical Design 23, no. 3 (February 20, 2017): 440–53. http://dx.doi.org/10.2174/1381612822666161026163201.

Full text
Abstract:
Background: The drug delivery of macromolecules such as proteins and peptides has become an important area of research and represents the fastest expanding share of the market for human medicines. The most common method for delivering macromolecules is parenterally. However parenteral administration of some therapeutic macromolecules has not been effective because of their rapid clearance from the body. As a result, most macromolecules are only therapeutically useful after multiple injections, which causes poor compliance and systemic side effects. Methods: Therefore, there is a need to improve delivery of therapeutic macromolecules to enable non-invasive delivery routes, less frequent dosing through controlled-release drug delivery, and improved drug targeting to increase efficacy and reduce side effects. Result: Non-invasive administration routes such as intranasal, pulmonary, transdermal, ocular and oral delivery have been attempted intensively by formulating macromolecules into nanoparticulate carriers system such as polymeric and lipidic nanoparticles. Conclusion: This review discusses barriers to drug delivery and current formulation technologies to overcome the unfavorable properties of macromolecules via non-invasive delivery (mainly intranasal, pulmonary, transdermal oral and ocular) with a focus on nanoparticulate carrier systems. This review also provided a summary and discussion of recent data on non-invasive delivery of macromolecules using nanoparticulate formulations.
APA, Harvard, Vancouver, ISO, and other styles
8

Pocock, Kyall, Ludivine C. Delon, Aparajita Khatri, Clive Prestidge, Rachel Gibson, Chris Barbe, and Benjamin Thierry. "Uptake of silica particulate drug carriers in an intestine-on-a-chip: towards a better in vitro model of nanoparticulate carrier and mucus interactions." Biomaterials Science 7, no. 6 (2019): 2410–20. http://dx.doi.org/10.1039/c9bm00058e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Costantino, Luca. "Drug delivery to the CNS and polymeric nanoparticulate carriers." Future Medicinal Chemistry 2, no. 11 (November 2010): 1681–701. http://dx.doi.org/10.4155/fmc.10.249.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bhosale, Rohit R., H. V. Gangadharappa, D. V. Gowda, Riyaz Ali M. Osmani, and Rudra Vaghela. "A Review on Nanocochleates: The Inimitable Nanoparticulate Drug Carriers." Advanced Science, Engineering and Medicine 9, no. 5 (May 1, 2017): 359–69. http://dx.doi.org/10.1166/asem.2017.2020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nanoparticulate Drug Carriers"

1

Sreeranjini, P. "Hyaluronic Acid Based Biodegradable Polyelectrolyte Nanocapsules and Modified Protein Nanoparticles for Targeted Delivery of Anticancer Agents." Thesis, 2015. http://etd.iisc.ac.in/handle/2005/4000.

Full text
Abstract:
Targeted delivery aids in minimizing most of the drug-originated systemic toxic effects as well as improving the pharmacokinetic properties of anticancer therapeutics. Tumor targeting using hyaluronic acid (HA) as the targeting ligand has attracted a great deal of interest among a host of strategies developed to target the overexpressed tumor specific receptors. HA is an endogenous molecule that possesses a lot of biological functions in the human body. The role of HA synthases, HA degrading enzymes and the interaction of HA with its primary receptor CD44 in tumor metastasis and angiogenesis is really complex and controversial to date. However, overexpression of CD44receptors on tumor surface has been well studied, which have been utilized to direct tumor targeted drugs. Most of the HA based targeting systems were HA drug conjugates and surface modified colloidal carriers which required covalent modification. The lack of accurate structural characterization of these systems resulted in modification of HA binding sites that could affect the efficient cellular uptake. LbL technique is a simple and facile method to incorporate several materials into polyelectrolyte assemblies for drug delivery applications. HA being a negatively charged polysaccharide can be easily incorporated into such systems without any covalent modification. Although HA based polyelectrolyte multilayer films and microcapsules have been reported in combination with polycations like PAH, PLL and chitosan, their application as targeted drug delivery systems have not yet been explored. Herein, two LbL architectures with HA as the terminal layer have been investigated as targeted drug carriers, which can recognize overexpressed CD44 receptors in metastatic breast cancer cells. In the first part of the thesis, a novel polyelectrolyte nanocapsule system composed of biopolymers HA and protamine sulphate (PR) as the wall components was prepared and characterized. These pH and enzyme responsive nanocapsules were then utilized for efficient loading and release of anticancer drug doxorubicin (dox). Higher drug release was observed in simulated intracellular conditions like acidic pH and presence of hyaluronidase enzyme as compared to physiological pH. In the second part of the thesis, dox incorporated bovine serum albumin (BSA) nanoparticles modified with HA-Poly(l-Lysine) multilayers were developed and characterized. The drug release pattern of the dox loaded BSA nanoparticles was found to depend on the presence of a protease enzyme trypsin than pH variations. Both of these drug delivery systems were then evaluated for their cell targeting efficiency and cytotoxicity in CD44+ positive metastatic breast cancer cell line MDA MB 231. The final layer HA facilitated targeted delivery of these drug carriers via CD44 receptor mediated endocytosis. The enhanced cellular uptake followed by sustained delivery of dox by virtue of slow intracellular enzymatic degradation of the drug carriers resulted in their improved cytotoxicity as compared to free dox. Further in vitro biodistribution and tumor suppression efficiency of both the systems were studied in breast cancer xenograft models using BALB/c nude mice. Enhance accumulation of dox in the tumor tissue and significant tumor reduction were observed when treated with encapsulated dox using the HA based nanocarriers as opposed to free dox.
APA, Harvard, Vancouver, ISO, and other styles
2

Sreeranjini, P. "Hyaluronic Acid Based Biodegradable Polyelectrolyte Nanocapsules and Modified Protein Nanoparticles for Targeted Delivery of Anticancer Agents." Thesis, 2015. http://etd.iisc.ernet.in/2005/3921.

Full text
Abstract:
Targeted delivery aids in minimizing most of the drug-originated systemic toxic effects as well as improving the pharmacokinetic properties of anticancer therapeutics. Tumor targeting using hyaluronic acid (HA) as the targeting ligand has attracted a great deal of interest among a host of strategies developed to target the overexpressed tumor specific receptors. HA is an endogenous molecule that possesses a lot of biological functions in the human body. The role of HA synthases, HA degrading enzymes and the interaction of HA with its primary receptor CD44 in tumor metastasis and angiogenesis is really complex and controversial to date. However, overexpression of CD44receptors on tumor surface has been well studied, which have been utilized to direct tumor targeted drugs. Most of the HA based targeting systems were HA drug conjugates and surface modified colloidal carriers which required covalent modification. The lack of accurate structural characterization of these systems resulted in modification of HA binding sites that could affect the efficient cellular uptake. LbL technique is a simple and facile method to incorporate several materials into polyelectrolyte assemblies for drug delivery applications. HA being a negatively charged polysaccharide can be easily incorporated into such systems without any covalent modification. Although HA based polyelectrolyte multilayer films and microcapsules have been reported in combination with polycations like PAH, PLL and chitosan, their application as targeted drug delivery systems have not yet been explored. Herein, two LbL architectures with HA as the terminal layer have been investigated as targeted drug carriers, which can recognize overexpressed CD44 receptors in metastatic breast cancer cells. In the first part of the thesis, a novel polyelectrolyte nanocapsule system composed of biopolymers HA and protamine sulphate (PR) as the wall components was prepared and characterized. These pH and enzyme responsive nanocapsules were then utilized for efficient loading and release of anticancer drug doxorubicin (dox). Higher drug release was observed in simulated intracellular conditions like acidic pH and presence of hyaluronidase enzyme as compared to physiological pH. In the second part of the thesis, dox incorporated bovine serum albumin (BSA) nanoparticles modified with HA-Poly(l-Lysine) multilayers were developed and characterized. The drug release pattern of the dox loaded BSA nanoparticles was found to depend on the presence of a protease enzyme trypsin than pH variations. Both of these drug delivery systems were then evaluated for their cell targeting efficiency and cytotoxicity in CD44+ positive metastatic breast cancer cell line MDA MB 231. The final layer HA facilitated targeted delivery of these drug carriers via CD44 receptor mediated endocytosis. The enhanced cellular uptake followed by sustained delivery of dox by virtue of slow intracellular enzymatic degradation of the drug carriers resulted in their improved cytotoxicity as compared to free dox. Further in vitro biodistribution and tumor suppression efficiency of both the systems were studied in breast cancer xenograft models using BALB/c nude mice. Enhance accumulation of dox in the tumor tissue and significant tumor reduction were observed when treated with encapsulated dox using the HA based nanocarriers as opposed to free dox.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Nanoparticulate Drug Carriers"

1

P, Torchilin V., ed. Nanoparticulates as drug carriers. London: Imperial College Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Thassu, Deepak, Yashwant Vishnupant Pathak, and Michel Deleers. Nanoparticulate Drug Delivery Systems. Taylor & Francis Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thassu, Deepak, Yashwant Vishnupant Pathak, and Michel Deleers. Nanoparticulate Drug Delivery Systems. Taylor & Francis Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Thassu, Deepak, Yashwant Vishnupant Pathak, and Michel Deleers. Nanoparticulate Drug Delivery Systems. Taylor & Francis Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Thassu, Deepak, Yashwant Vishnupant Pathak, and Michel Deleers. Nanoparticulate Drug Delivery Systems. Taylor & Francis Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

(Editor), Deepak Thassu, Michel Deleers (Editor), and Yashwant Pathak (Editor), eds. Nanoparticulate Drug Delivery Systems (Drugs and the Pharmaceutical Sciences). Informa Healthcare, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nanoparticulates As Drug Carriers. Imperial College Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Torchilin, Vladimir P. Nanoparticulates as Drug Carriers. PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO., 2006. http://dx.doi.org/10.1142/p432.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Nanoparticulate Drug Carriers"

1

Rehman, Nahid, and Anjana Pandey. "Nanoparticulate Carriers Used as Vaccine Adjuvant Delivery Systems." In Engineered Nanoparticles as Drug Delivery Systems, 91–100. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003252122-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Patravale, Vandana, Prajakta Dandekar, and Ratnesh Jain. "Nanoparticles as drug carriers." In Nanoparticulate Drug Delivery, 29–85. Elsevier, 2012. http://dx.doi.org/10.1533/9781908818195.29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Patravale, Vandana, Prajakta Dandekar, and Ratnesh Jain. "Characterization techniques for nanoparticulate carriers." In Nanoparticulate Drug Delivery, 87–121. Elsevier, 2012. http://dx.doi.org/10.1533/9781908818195.87.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patravale, Vandana, Prajakta Dandekar, and Ratnesh Jain. "Nanoparticulate systems as drug carriers: the need." In Nanoparticulate Drug Delivery, 1–28. Elsevier, 2012. http://dx.doi.org/10.1533/9781908818195.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Svenson, Sőnke, and Donald A. Tomalia. "Dendrimers as Nanoparticulate Drug Carriers." In Nanoparticulates as Drug Carriers, 277–306. PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO., 2006. http://dx.doi.org/10.1142/9781860949074_0013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kreuter, Jörg. "Nanoparticulate Carriers for Drug Delivery to the Brain." In Nanoparticulates as Drug Carriers, 527–47. PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO., 2006. http://dx.doi.org/10.1142/9781860949074_0024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Basu, Mukul Kumar, and Sanchaita Lala. "Nanoparticulate Drug Delivery to the Reticuloendothelial System and to Associated Disorders." In Nanoparticulates as Drug Carriers, 463–80. PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO., 2006. http://dx.doi.org/10.1142/9781860949074_0021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cohen-Sela, Einat, Victoria Elazar, Hila Epstein-Barash, and Gershon Golomb. "Nano-Carriers of Drugs and Genes for the Treatment of Restenosis." In Nanoparticulate Drug Delivery Systems, 235–69. CRC Press, 2007. http://dx.doi.org/10.1201/9781420008449-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Souto, Eliana B., and Rainer H. Müller. "Lipid Nanoparticles (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers) for Cosmetic, Dermal, and Transdermal Applications." In Nanoparticulate Drug Delivery Systems, 213–33. CRC Press, 2007. http://dx.doi.org/10.1201/9781420008449-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gheidari, Davood, and Mohammad Bayat. "Current treads of targeted nanoparticulate carriers for the treatment of Alzheimer’s disease." In Nanomedical Drug Delivery for Neurodegenerative Diseases, 17–39. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-323-85544-0.00005-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nanoparticulate Drug Carriers' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography